Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
David Macias, Stephen Moore, Alexi Crosby, Mark Southwood, Xinlin Du, Huiling Tan, Shanhai Xie, Arlette Vassallo, Alexander J.T. Wood, Eli M. Wallace, Andrew S. Cowburn. Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension. Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019

Member's Comments

No comment yet.

Related content which might interest you: Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 Novel insights into the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary vascular diseases Year: 2020 The pathophysiological role of novel pulmonary arterial hypertension gene SOX17 Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020 Year: 2021 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Novel biomarkers in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Identification of treatment goals in paediatric pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 1616-1626 Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Novel techniques for advancing our understanding of pulmonary arterial hypertension Source: Eur Respir J, 53 (5) 1900556; 10.1183/13993003.00556-2019 Year: 2019 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020